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CHAPTER I 
 
ULTRASOUND-INDUCED CANCER IMMUNOTHERAPY: PRIMED FOR SUCCESS? 
 
Background Overview 
 
Significant advances in breast cancer research have led to improvements in screening and 
therapy, including breast conserving surgery1, platinum-based chemotherapies1,2, tumor cell receptor-
targeted therapies1–3, angiogenesis-targeted therapies2, cell cycle-targeted therapies2,3, and immune 
therapies2. Breast cancer, however, is still the second leading cause of cancer related deaths in women. 
General medicine, and cancer in particular, have experienced a fundamental shift in the focus of research; 
the idea of ‘one size fits all’ medicine is being revised by the understanding that patient-to-patient 
differences render effects of identical treatments from potent in some patients to ineffective in others. 
The result has been a paradigm transformation with the goal of generating robust therapeutic response 
in all patients based on therapeutic approaches tailored and personalized for each individual. 
One promising branch of personalized cancer research is immunotherapy, in which treatments 
aim to enhance and arm a patient’s own immune system against tumor cells. The immune system is an 
ideal therapeutic option for cancer given its basic attributes for targeting specificity, systemic surveillance, 
and long-term memory. While normally effective for anti-tumor surveillance, cancer immunity can be 
reduced by accumulated changes in the tumor microenvironment4.  
The potential for immunotherapy is evidenced by reports dating back centuries5,6, long before the 
elucidation of specific immune involvement and mechanisms. More recently, a number of cancer 
immunotherapies have been developed from the personalized era of medicine, including monocloncal 
antibodies7–9, adoptive T cell transfer4,10,11, and the infusion of donor immune cells12. Despite promise, 
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these treatments have demonstrated drawbacks and limitations discussed below in the “Cancer and the 
Immune System” section.   
Another less-explored cancer immunotherapeutic option involves generating acute local 
inflammation intended to overcome tumor microenvironment-induced immune suppression4,13. 
Furthermore, numerous cases have been reported of an ‘abscopal’ effect – or distant bystander effect – 
where local inflammatory treatments in tumors, even of a palliative nature, trigger regression of distant, 
untreated tumors14–16. Research focused on eliciting this immune-mediated abscopal effect holds 
significant promise for metastatic disease, but variation among methods and resulting reports of efficacy 
is a barrier to progress14. One specific method for inducing systemic immunity to cancer, which holds 
considerable promise, involves the use of therapeutic ultrasound17. In this overview, we address the 
fundamental principles of cancer, immunology, and therapeutic ultrasound, and examine evidence 
supporting ultrasound-induced cancer immunotherapy. 
 
Breast Cancer Basics 
One in eight women will be diagnosed with breast cancer in her lifetime.18 Breast cancer is 
primarily classified into three categories based on gene expression profiling and receptors available for 
targeted therapy.19 Luminal cell breast cancers typically overexpress estrogen receptors (ER+), 
progesterone receptors (PR+), or both (ER+/PR+).19 Human endothelial growth factor receptor (HER2+) 
breast cancers overexpress HER2, a membrane receptor of the epidermal growth factor receptor 
family.3,19 While ER/PR/HER2 status provide options for targeted therapeutics, basal cell breast cancers 
generally lack targetable receptors (ER-/PR-/HER2-) and are referred to as triple negative breast cancers.19 
The identification of unique molecular markers for HER2+ and ER+/PR+ breast cancers have led to the 
development of targeted therapeutics, but de novo resistance and acquired resistance continue to limit 
success of targeted therapies1,8. Breast tumors are often heterogeneous in their cellular composition, 
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further complicating therapeutic efforts. While targeted therapies are often effective for the majority of 
cell types in a tumor, remaining cells may continue disease progression along with any targeted cells that 
have acquired resistance to therapy.1,8 
The primary concern associated with breast cancer is metastatic progression resulting in 
functional impediment of vital organs18. In the United States, improved screening has led to an increase 
in early stage breast cancer diagnoses, but no significant change in the number of cases which are 
metastatic disease at initial presentation (Figure 1)20. Even with the use of treatment options for primary 
breast cancer, including surgical tumor resection, removal of downstream lymph nodes, radiation therapy, 
chemotherapy, and targeted therapies, 20-30% of invasive breast cancer patients will develop recurrent 
disease, often at metastatic sites.18,21 Whether metastatic at initial diagnosis or with disease recurrence, 
no cure exists for metastatic breast cancer, lending to a median survival of 3 years once metastatic disease 
is identified.18,22 Development of effective, durable therapies for metastatic disease is a challenge that 
must be overcome to eliminate the mortality associated with breast cancer. 
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Figure 1. Incidence of cancer that was metastatic at first presentation, United States, 1975-2012. Data 
are for breast cancer (SEER historic stage distant) among women 40 years of age or older and prostate 
cancer (American Joint Committee Stage IV) among men 40 years of age or older. Reproduced with 
permission from Welch et al,20 Copyright Massachusetts Medical Society. 
 
Immunology Basics 
The immune system, designed to protect the host from foreign invaders, is a complex, multi-
layered network. The first layer provides a physical barrier to help prevent initial invasion of the host13,23. 
This layer comprises the skin and mucous membranes.23,24 Any discontinuity in the barrier, however, such 
as a wound, provides a direct path for microorganisms to enter and attack the host. Innate immunity, the 
second layer of immune defense, provides a rapid immune response to trap and eliminate foreign 
bodies23–25. Adaptive immunity is the third layer of the system, and has been identified in approximately 
1% of animals23. The adaptive response is tailor-made (“adapted”) to target a specific invader, and to 
create a thorough, effective elimination of the foreign microorganism25. 
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The innate and adaptive systems have distinctly separate, broad functions in an immune 
response. The innate system is the rapid-response team. It simultaneously isolates the affected tissue, 
launches a primary defensive attack on the assailing microorganism, and recruits other immune cells to 
the site for assistance.23–25 Cells of the body express “self” surface markers which indicate to immune cells 
that they are not a threat and do not warrant an attack by the immune system.23,25 Invading pathogens 
do not express the same markers as the host’s “self” cells, but instead express other unique surface 
markers, as well as some which are common among microorganisms.23–25 These surface markers allow 
cells of the innate system to identify “non-self” cells as foreign invaders. While sufficient to eliminate small 
infections, the innate system is incapable of mounting a robust attack without aid.23  
Adaptive immunity, as its name suggests, is designed to adapt to a specific, existing threat.23–25 To 
activate this arm of the immune response, the innate system alerts the adaptive system to the foreign 
presence and provides information about the invader.23–25 The adaptive system tailors some of its cells 
based on information from the invaders to develop cells specifically able to grow, divide, and eliminate 
the threat.23,25 This response is robust in both cell number and targeting specificity; however the need to 
modify and then expand cells to generate a significant response requires time, up to a week for some 
adaptive cell types.23,25 The adaptive system provides an additional benefit – once the infection has been 
eliminated, most of the adaptive cells involved in the specific response are eliminated because there is no 
longer a need for them, but a few are kept in circulation.23,25 These circulating cells impart a memory 
capacity to the host’s immunity and are capable of mounting a substantially faster response if that invader 
is subsequently encountered in the future.23,25 An effective way to leverage this aspect of immunity is 
vaccinations, which present the body with a dead or weakened form of a microorganism to induce 
adaptive memory cells; if the active pathogen is encountered later, the body responds in a rapid and 
robust manner to eliminate the infection23. 
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Cancer and the Immune System 
In addition to targeting “non-self” invading pathogens, the immune system is also able to 
differentiate “self” cells from “altered-self” cells11,26. For example, tumor cells express altered levels and 
mutated versions of normal “self” surface markers making them identifiable by immune cells26. Despite 
the broad capacity of the immune system, tumors are highly adaptable, enabling changes that reduce 
immunorecognition.27 Accumulated mutations eventually modify the tumor microenvironment,  including 
cells in the tumor and surrounding tissue, toward pro-tumor, anti-host activity.27–30 Immunoediting is the 
process by which the tumor cells interact with the host’s immune system, and it encompasses the induced 
immune-suppressor/tumor-suppressor dichotomy.28–30 The immunosuppressive nature of tumors stems 
from a variety of mechanisms working together to limit recruitment of activated immune cells, down-
regulate stimulatory ligands, up-regulate immune inhibitory signaling, and elevate retention of immune 
regulatory cells.11,31  Tumors are typically in a protective state of mild, chronic inflammation resembling a 
healing wound4,32,33. As such, generating an acute inflammatory response in the tumor may recruit 
immune cells into the microenvironment, subverting the immune suppressive tumor mechanisms34. The 
characteristics of the immune system make it perfectly poised for an effective anti-tumor response, 
specifically three primary attributes: 1) ability to distinguish self from altered-self, 2) high specificity of the 
adaptive immune response, and 3) the long-term retention of immune memory cells for systemic 
surveillance 
In 1891, William B. Coley demonstrated some of the first evidence for immune modulation in 
tumors as a potential treatment option.5 Limitations in understanding the immune system caused many 
in the field to doubt Coley’s findings. The advent of radiation and chemotherapy as effective cancer 
treatments ended the search for immunotherapy options.5,7 Cancer-related immune research did not 
resurface until 1957 when Frank McFarlane Burnet proposed that the immune system could distinguish 
between cancer cells and normal cells.7,35 Subsequent immunotherapy research, particularly in recent 
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decades, has demonstrated high potential and moderate success at both local and systemic levels. 
Currently approved immune-based cancer therapeutics have been summarized by Li, et al in Table 1.7  
 
Table 1. Examples of FDA-approved cancer immunotherapeutic agents. (Table reproduced from Li et al.,7 
with permission license provided by Creative Commons.36)  
 
  
Antibody therapies rely on mutated surface expression (“altered self”) of cancer cells, and act 
through surface receptors, immune modulation, or conjugated drug delivery8. Significant limitations lie in 
short circulation half-life9, off target effects from systemic administration9, and resistance, both de novo 
and acquired37. Tumor vaccination and T cell transfer methods both aim to arm the patient’s adaptive 
immune cells by providing the cells with the ‘best’ tumor-targeting antigens on an individualized patient 
level4. These options are limited by immune competence of the patient, suppressive tumor 
microenvironment, and resistance4. 
Evidence of anti-tumor immune stimulation at sites distant to the local site of treatment, the 
abscopal effect, provides precedent for localized immunotherapy as an effective treatment for metastatic 
disease14,15. Optimal immunotherapy would engage adaptive immunity to generate a therapeutic 
response which specifically targets a patient’s unique tumor cells, systemically clears metastatic tumors, 
and effectively retains memory cells to eliminate recurrent tumors. Ultrasound is one promising method 
to induce the localized acute inflammation needed for such immunotherapeutic options38. 
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Ultrasound 
Diagnostic ultrasound is a non-invasive, non-ionizing imaging technique, making it safe for many 
applications, including pre-natal imaging. Ultrasonic technology also has applications in a therapeutic 
capacity, which were recognized in 1927, even before its potential for diagnostics38,39. Research into 
therapeutic ultrasound has increased in recent years due to the availability of improved technology to 
generate and accurately measure ultrasound power40. Diagnostic ultrasound operates at a frequency of 
approximately 5 MHz, while the therapeutic range is 20 kHz to 3 MHz41 (see Figure 2). Ultrasonic therapies 
fall into two general categories of power: low and high38. Low power uses include transdermal delivery of 
topical drugs and vaccines17,42, sonoporation38, thrombolysis17,43, and physiotherapy17,40. High power 
ultrasound is employed in treatment of kidney stones40 and tumors17,38,40.  
 
 
Figure 2. General classification of the frequency ranges of ultrasound. (Figure adapted and reprinted from 
Ultrasonics Sonochemistry, 11(2), Yu et al, A review of research into the uses of  low level ultrasound in 
cancer therapy, Pages 95-103, Copyright 2004, with permission from Elsevier .40) 
 
Different than diagnostic ultrasound, which seeks to limit cellular effects,38,41 therapeutic 
ultrasound aims to create effects, reversible and permanent, at the cellular level.38 Biological effects of 
therapeutic ultrasound can be precisely tuned with selection of ultrasound parameters for controlled 
energy deposition in tissue, specifically the amount and type of energy, which may be thermal, 
mechanical, or a combination.38,44,45  
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Generation of a thermal increase in a targeted tissue has numerous biological consequences, 
ranging from mild hyperthermia to thermal ablation. Thermal change is created when the tissue incident 
to the beam absorbs energy from the ultrasonic waves46. The effects of thermal therapy are dependent 
on a number of characteristics including physical tissue properties (i.e. size, density, perfusion), thermal 
properties of tissue, peak temperature applied, and duration of thermal application.46,47 To account for 
these variations, the cumulative equivalent minutes at 43 ⁰C (CEM43) calculation was developed for 
quantitative dosimetry during thermal therapeutics.48 Analysis of compiled temperature-death data from 
cells in vitro by Dewey,49 found that above 43 ⁰C thermal treatment of cells in vitro resulted in exponential 
cell death.47 The equation is CEM43 = ∫ 𝑡𝑖 ∗ 𝑅
(43−𝑇𝑖)
𝑖
0
, where t is the given time interval (i), T is the average 
temperature during the interval 0:i, and R is a term to account for temperature-related cell death, where  
R = ¼ for Ti less than 43 ⁰C, and R = ½ otherwise.47 This provides a useful quantitative measure of thermal 
dosing, which can be compared across methods and instruments to overcome dosimetry differences and 
limit the subsequent variability of reported bioeffects. Recent advances in magnetic resonance (MR) 
technology have led to the development of MR-thermometry, a technique for thermal mapping which 
utilizes temperature-based changes in proton-resonance.50,51 MR-thermometry may be used in 
conjunction with therapeutic ultrasound to precisely measure thermal changes in tissue, which can be 
mapped onto an MR image, in real time, to display CEM43 as a function of time.50,52,53   
Mechanical ultrasound events are generated with large pressure oscillations over short pulses of 
application.54 Acoustic streaming and acoustic cavitation are two types of mechanically-induced biological 
effects of ultrasound. Acoustic streaming relates to the motion experienced by molecules and organelles 
in the path of ultrasound propagation. Structures held in place by adhesions and extracellular matrix 
remain fixed, while fluid and small molecules are free to flow around the stationary objects. Acoustic 
cavitation relies on the presence of stable gas microbubbles in the tissue, which interact with the pressure 
oscillations causing miniature explosions, subsequently damaging surrounding tissue.55 Similar to the 
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quantification of ultrasound thermal dosimetry by CEM43, the mechanical effect of therapeutic 
ultrasound is measured with mechanical index (MI).56 The MI is related to peak negative pressure of the 
pulse divided by the center frequency.44,56,57 Shortcomings have been identified with MI, including the 
absence of a term to account for exposure time44, temperature of the tissue44, and multiple exposures56. 
 
FUS-Induced Anti-Tumor Immune Response 
Previous studies have examined FUS in the context of tumor treatment54. Many early studies 
primarily used FUS for non-invasive ablation of tumors as a surgical alternative.50,53,58,59 A variety of FUS 
treatment parameters have been examined to assess the immunostimulatory impacts in the tumor milieu. 
Hu et. al. compared mechanical and thermal FUS ex vivo and determined that debris from tumors treated 
with mechanical FUS more effectively stimulated dendritic cells and macrophages for anti-tumor 
activity.60,61 Some additional studies of FUS-induced anti-tumor immune response include: sparse 
arrangement of small, thermal lesions within tumors to avoid whole-tumor ablation,62 sub-ablative levels 
of hyperthermia for moderation of the tumor microenvironment and immune activity,63 sub-ablative 
hyperthermia in combination with immunomodulatory agents,64 and the use of FUS for tumor vaccine 
strategies.65,66 
 
Conclusion 
 
The promise held by cancer immunotherapy has transitioned research towards more immuno-
centric goals.  Previous studies in cancer, immunotherapy, and FUS result in an expansive field with 
exciting potential for the synthesis of effective FUS-induced anti-tumor immunotherapies. Specifically, 
there is a need for an experimental framework which thoroughly, reproducibly, and quantitatively 
assesses response to treatment. The complexity of immune cells involved, their respective response 
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kinetics, and microenvironmental signaling processes necessitates the use of multiplexed response 
characterization to conclusively infer therapeutic efficacy. 
Cancer immunotherapy has the potential to revolutionize the standards to cancer therapy and 
prognosis. While generating relevant, durable immunotherapeutic responses has proved difficult, 
substantial evidence suggests its clinical feasibility. Therapeutic ultrasound is a promising method for 
cancer immunotherapy given its non-invasive, non-ionizing nature, and highly tunable properties.   
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CHAPTER II 
 
FOCUSED ULTRASOUND INDUCED CANCER IMMUNOTHERAPY IN A MAMMARY TUMOR MODEL 
 
Background Overview 
 
The application of focused ultrasound to tumors in a murine model of breast cancer was used for 
the purpose of generating an anti-tumor immune response. A critical component required for thorough 
characterization of response to FUS-induced cancer immunotherapy involves evaluation of the cellular 
responses as a function of stimulus. In this study, we use a reporter mouse model of spontaneous breast 
cancer for in vivo bioluminescent imaging to track NF-κB activation, which is a central mediator of 
inflammation and cancer development processes.67–70 The time course of NF-κB activation is used to 
inform the timing of tissue isolation for immune assessments. Treated, untreated, and contralateral tumor 
tissues and spleens were analyzed by flow cytometry, immunohistochemistry (IHC), and cytokine bead 
array to characterize changes in the cellular and effector response following FUS.  
 
Cancer Immunotherapy Targets and Barriers 
Cancer immunotherapy takes the concept of personalized medicine to arm a patient’s own 
immune system against their unique tumor cells. Successful induction of anti-tumor immunity has been 
demonstrated to produce complete, lasting remission in patients, but responses have been 
inconsistent11,71–73. Complexities of the immune system, such as response to environmental signaling and 
activation/suppression balance, complicate reproducible success of anti-tumor immunotherapies.  
 Immune cells in the tumor microenvironment are subject to tumor-produced cytokines and other 
signaling effectors, which shift immune cells to pro-tumor phenotypes, suppressing anti-tumor 
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responses31,74–76. Many therapies seek to activate immune cells and inhibit immune suppressors with the 
goal of shifting the anti-tumor/pro-tumor dichotomy towards an anti-tumor effect. Dendritic cell 
vaccines77 and adoptive T cell transfer10,11,78 seek to activate immune cells in a manner specifically targeted 
to tumor cells, while antibodies against cytotoxic T lymphocyte associated antigen 4 (CTLA-4)79,80, 
programmed cell death protein 1 (PD1)79–82, and programmed cell death ligand 1 (PD-L1)81 target immune 
checkpoints to selectively suppress immunoregulation. Immunotherapy research has spanned the range 
of the immune system: dendritic cells62,83–86, macrophages33,87, and T lymphocytes10,88 are a few of the 
immune targets currently being explored.  
As adaptive immune cells, T lymphocytes are of particular interest due to their capacity to target 
tumor cells with high specificity in virtually all tissues7,11,89, and retain a population of memory T cells for 
long-term surveillance7,11. Multiple T cell phenotypes exist and serve immunostimulatory and 
immunosuppressive roles in the tumor microenvironment34,90. Cytotoxic T lymphocytes (CTLs) have been 
identified as a key player in effective tumor elimination, directly engaging with, and destroying, tumor 
cells88,91. Helper T cells (Thelper) have an immune-supportive role, assisting and maintaining CTL activation 
through a variety of mechanisms, including interactions with antigen-presenting cells and production of 
stimulatory cytokines92,93.   Additionally, Thelper cells help CTLs develop a subset of memory cells, necessary 
for potential long-term, anti-tumor response to recurrent disease92,93. In contrast to these two 
immunostimulatory T cell phenotypes, regulatory T cells (Tregs) serve an immunosuppressive role. In non-
tumor environments, Tregs are critical in proper maintaining proper immune functionality, serving as a 
negative feedback control in the balanced system93–96. Tregs balance CTL activation to ensure that the 
magnitude of immune response is appropriate to the present threat, and to end the response once the 
threat is eliminated95. In the tumor milieu, however, Treg activity has a tumor-
supportive/immunosuppressive function, preventing activation of CTLs and forestalling cytotoxic 
elimination of tumor cells92,96. Cell phenotypes are identified with antibody labeling for phenotype-specific 
14 
 
cellular markers. T cells are generally discerned by the presence of CD3 surface receptor97, and subsequent 
phenotypes can be distinguished by presence of CD8 (CTLs)98,99, CD4 (Thelpers and Tregs)95, and FoxP3 (Tregs)95. 
The amount and phenotype of T cell infiltrates within tumors have prognostic value for response to 
immunotherapy100. Additionally, studies have identified increased CD4+/CD8+ T cell ratio as evidence of 
an anti-tumor response, further indicating the critical supportive role of CD4+ Thelpers90. The Immunoscore 
technique, developed to describe the distribution of immune phenotypes in the tumor, is an effective 
prognostic measure for immunotherapeutic response101,102.  
Barriers, both physical and chemical, are created by tumors to evade immune detection and limit 
immunogenicity4. Generation of effective anti-tumor immunity requires two key components: 1) 
infiltration of immune cells into the tumor, and 2) reversal of the tumor microenvironment (TME) for anti-
tumor activation of the tumor-infiltrating immune cells. Acute inflammation (i.e. injury and infection) 
induces immune cell recruitment, providing a direct method to overcome some tumor barriers. Induction 
of an injury in the tumor may cause sufficient inflammation to recruit immune cells under the pretense of 
wound-healing. Once inside the tumor, immune cells may be able to recognize, target, and eliminate 
tumor cells. Immune cells, particularly those of the adaptive system, depend on protein-based antigen 
expression by tumors to develop tumor cell-specific recognition targeting. We hypothesize that the 
induced injury must be sufficient to elicit acute inflammation without denaturing the tumor-specific 
antigens which drive adaptive immune recognition patterning.  
 
Cytokines in the Tumor Microenvironment 
 Cytokines are signaling molecules that serve as indirect lines of communication between cells, 
with a prominent role in the processes of immune cells23,103. The ability of cytokines to activate or suppress 
immune response is of particular interest for cancer immunotherapy research103,104. Interleukin (IL)-2 and 
interferon (IFN)-α are two cytokines approved by the FDA for the treatment of melanoma, with IFN-α also 
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approved to treat metastatic renal cell carcinoma103. The prevalence of signaling network redundancies 
and pleiotropic functions are limitations for cytokine-based immunotherapies and necessitate 
multiplexed cytokine measurements to characterize tumor immune environment103,104. This brief 
overview serves to identify and broadly classify the effects of several key cytokines in the tumor 
immunotherapy milieu.  
Table 2 (adapted from Lee et al103) summarizes seven cytokines and several of their primary roles 
in immune signaling. IL-1β is involved in dendritic cell maturation, critical for effective antigen 
presentation to naïve T cells103. A pro-inflammatory subclass of Thelper cells, type 1 Thelper cells (Th1), are the 
primary source of IL-2, a cytokine necessary to achieve a robust anti-tumor immune response with 
sufficient activation and expansion of T cells.103. Tumor necrosis factor (TNF) is a potent 
immunostimulatory cytokine that can induce killing of tumor cells via recruitment and activation of 
macrophages, neutrophils, natural killer cells, and DCs23,103. Another strong immunostimulatory cytokine, 
interferon gamma (IFN-γ), is produced by a variety of immune cells, including Thelper cells, macrophages, 
and NK cells, to activate macrophages, increase expression of MHC class I and class II molecules for 
improved antigen presentation, and encourage Thelper differentiation of CD4+ T cells103. IL-6 acts as a potent 
immunostimulatory cytokine, promoting T cell proliferation, CD8+ T cell infiltration into tumors, and 
shifting naïve CD4+ T cells towards a Thelper 17 (Th17) phenotype instead of a suppressive Treg 
phenotype105. Th17 cells produce IL-17, IL-2, TNF, and IFN-γ, and generate a pro-inflammatory response 
which may be important in anti-tumor immunity106.  In contrast to the anti-tumorigenic effects of these 
pro-inflammatory cytokines, effects of IL-10 are predominantly immunosuppressive including increased 
generation of Tregs, as well as down-regulation of MHC class II expression on—and inhibition of—
macrophages and DCs103. 
While some primary functions of individual cytokines have been described here, this summary 
presents a simplified view of inherently complex signaling interactions. Recent research in the field 
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indicates that cytokines are produced by—and act upon—a variety of cell types103. As a result, each 
cytokine influences a multitude of immunological effects, both immunostimulatory and 
immunosuppressive, dependent upon the specific context of interest103,105.  
 
Table 2. General features of select cytokines. (Table adapted from Lee and Margolin103, with permission 
license provided by Creative Commons107. *Sompayrac23)  
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Therapeutic Development Limitations 
Advances in cellular and molecular analysis techniques have improved mechanistic 
understandings of disease and response to therapy. However, the need for biological samples (i.e. tissues) 
is a limiting factor in research progress. There is a need for methods to inform time point decisions for 
tissue collection. The temporal, dynamic changes in immune response to stimulus often require the 
collection of tissue samples at multiple time points to assess immune kinetics. This can be challenging due 
to the destructive nature of tissue recovery, which often necessitates collection of whole organs for 
animal models and biopsy specimens for human studies.  While theoretically optimal, cellular and 
molecular analysis of biological samples collected at multiple time points has practical limitations, 
including time and financial feasibility. A statistically significant number of animals are needed at each 
time point, for each treatment group and corresponding control groups. Furthermore, sufficiently high 
sampling frequency in the temporal dimension is required to develop a representative view of the 
response, like an immune Nyquist frequency. Researchers must, therefore, select a limited number of 
collection time points to maintain experimental feasibility; however, if the time points selected are 
misguided, the tissue-based characterizations may not accurately represent the biological dynamics due 
to under sampling.  
 
Bioluminescence in vivo Imaging 
Development of in vivo imaging techniques, such as MR imaging, positron emission tomography, 
and bioluminescent imaging (BLI), have created an opportunity to monitor specific aspects of therapeutic 
response in animal studies with minimal invasiveness108. Imaging may be used to acquire data multiple 
times within a subject, including pre- and post-treatment information, so that controls may be subject-
relative. Compared to other in vivo imaging methods, BLI technology affords imaging which is relatively 
simple, low cost, high sensitivity, and non-ionizing109–111. Typically, the firefly luciferase gene is transfected 
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into a DNA sequence downstream of a selected promoter sequence, such that promoter activation results 
in luciferase protein production110,112. Luciferin is then introduced (injected in vivo or with media in vitro) 
and, in the presence of oxygen and ATP, is oxidized by luciferase to form oxy-luciferin, which emits a 
photon in the process of relaxing from an excited state to ground state110,112,113. These photons scatter 
through the tissue and are detected by a charge-coupled device (CCD) camera, which bins photons, 
according to user-defined settings, to spatially identify bioluminescent sources109. The resulting two-
dimensional photon map is overlaid on a photograph, acquired in tandem with BLI, for bioluminescent 
information which is co-registered with subject anatomy109. A variety of transgenic models have been 
developed for BLI, including transplantable cell lines, constitutively active spontaneous tumor models, and 
conditional activation models108,112,114,115. In this way, biological events coupled to the production of 
luciferase can be non-destructively and quantitatively characterized in complex living subjects by BLI. 
 
Integral Role of the NF-κB Pathway in Cancer 
Ubiquitous as a transcription factor, NF-κB is critically involved in many biological functions and is 
the basis for an expansive field of published literature.116–118 This brief overview of NF-κB serves only as a 
primer for some of the functions which are most relevant in the context of the experimental work 
described here, and is not an exhaustive review of its effects. NF-κB plays a variety of roles in cancer and 
immunity dependent upon cell type and stage of tumor development, and is a central mediator of 
processes involved in tumor growth, apoptosis inhibition, metastatic progression, and inflammation, both 
chronic and acute67,69,70,119–123. Within the context of immunity, NF-κB is involved in processes of immune 
cell development,69,124 production of immunomodulatory cytokines,67,113,122,125 and leukocyte recruitment 
by regulation of adhesion molecules.122   Furthermore, studies have demonstrated a duality: NF-κB activity 
may be pro-tumor or anti-tumor depending on cellular and environmental context.  
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Experimental Overview 
We have generated a novel double-transgenic murine reporter model of cancer. This new model, 
PyNGL, incorporates spontaneous tumor formation and metastatic disease progression characteristics of 
the MMTV-PyMT (Polyoma) model of breast cancer126 with in vivo NF-κB pathway reporter capabilities of 
the NF-κB-GFP-luciferase (NGL) model112. The immunocompetence of both the MMTV-PyMT and NGL 
models is supportive of PyNGL immunocompetence, with spontaneous formation of multiple mammary 
fat pad tumors, potential for metastatic progression to lungs, and the NF-κB reporter for in vivo 
bioluminescent imaging. PyNGL tumors were treated using focused ultrasound for the purpose of 
triggering inflammation-induced anti-tumor immunity, and in vivo BLI was used to monitor changes in 
local and systemic NF-κB activation. 
 
Methods 
 
Generation of Novel PyNGL Murine Model 
 An F1 breeding strategy was implemented to create the PyNGL murine model. Both MMTV-PyMT 
tumor and NGL luciferase genes are dominant, so MMTV-PyMT positive males were bred with 
homozygous NGL positive females. With this breeding strategy, 100% of offspring were heterozygous for 
the NGL trait, approximately 50% were heterozygous for the MMTV-PyMT trait (assume trait is evenly 
distributed between genders), and 50% of offspring will be female; this resulted in 25% of total offspring 
that were females with PyMT and NGL genetics. The use of homozygous NGL female breeders allowed 
this double-transgenic strategy to maintain the same efficiency of target offspring production as single-
transgenic PyMT breeding.   
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Bioluminescent in vivo Imaging 
 At least 24 hours prior to imaging, an electric razor was used to shave the anterior surface of the 
mouse including the thorax and abdomen, and then a depilatory cream (Nair, Church & Dwight Co., Inc., 
Ewing, NJ) was applied for 90 seconds to the shaved region before removal with water. An In Vivo Imaging 
System (IVIS) Lumina Series III (Caliper Life Sciences, PerkinElmer acquisition, Waltham, MA) was used to 
measure bioluminescence in PyNGL mice following intraperitoneal injection of 0.1 mL luciferin D-firefly in 
PBS (10 mg/mL; Biosynth L-8240). Images were acquired with 7-second exposure, unless otherwise 
noted, and a sequence setup was used to acquire one image every minute for 40 minutes. During each 
session, 1-3 mice were placed on the IVIS platform for imaging of the flank or tumors. The mice were 
placed either: 1) prone for flank imaging of NGL mice, or 2) supine for tumor imaging of PyNGL mice with 
the paws loosely taped to the IVIS platform to expose the anterior surface during imaging. Prior to 
treatment (FUS or no treatment), 1-3 baseline (pre-treatment) IVIS time points were collected; for both 
untreated and FUS-treated mice, this timing was determined by size of the largest tumor, selected for a 
maximal dimension of 1-1.5 cm. Mice were imaged at multiple time points after treatment, with a 
minimum of 12 hours between IVIS imaging sessions for up to 6 days, followed by up to 4 imaging sessions 
per week, at least 24 hours apart, until euthanasia. Mice underwent a maximum of 20 total IVIS imaging 
sessions. 
 
IVIS Image Processing Technique 
 Regions of interest (ROIs) were defined for each mouse to include the head (R1 – Figure 3) and 
two mammary tumors (R2 and R3 – Figure 3). These ROIs were placed on each sequential image (Si – Figure 
3) within a time point (Tj – Figure 3). Adjustments were made for placement of ROIs between time-point 
imaging sessions of a particular mouse, such that anatomical localization was maintained, despite minor 
variations in subject placement. Average radiance was measured in the ROIs for every image within each 
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imaging session and at all time points. Within each time point, the maximum value of average radiance 
was selected for each R (Figure 3A); this can be thought of as the “true average radiance,” as it accounts 
for timing variations in delivery and metabolism of luciferin, which may result from factors including 
altered tumor vascularization127,128 and luciferin dosage127 (see Figure 7 for empirical support). A two-step 
normalization process (Figure 3B) was then used to measure ROI radiance with respect to baseline and 
account for day-to-day variations in signal due to stress or other systemic factors.  This two-step process 
(Figure 3) includes 1) normalization of ROIs in each time-point to their respective baseline time-point 
values, then 2) normalization within each time-point of the tumor ROIs to the head ROI. Generally, step 
one sets up the framework for BLI analyses to assess response as a relative change from baseline, while 
step two accounts for day-to-day systemic luminescence variations due to luciferin injections and stress-
induced NF-κB activity. The ubiquitous nature of NF-κB throughout the body, and the particularly high 
background activity levels in tumors, necessitated BLI quantification methods with high sensitivity. This 
need was realized with the use of true average radiance within each time-point ROI and the 
implementation of a two-step normalization process.  
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Figure 3. ROI analysis and normalization process. (A) For every time point, T(1:X), there are a sequence of 
40 images, S(1:Y), where a delay of 60 seconds separates sequential images. Within each image, there are 
3 regions of interest selected for analysis: R1 is the head, R2 is one tumor, and R3 is a second tumor. Within 
each time point Tj, the value of each region of interest Rk is determined for all Si as rik. For Tj, the maximum 
value of r(1:Y)k for each Rk is identified as mjk. (B) A two-step normalization process of the mjk matrix is used. 
First, each R is normalized by dividing each time point by the initial time point (T1), resulting in a new 
matrix of baseline-normalized values, bjk. Baseline-normalization allows data from each time point to be 
assessed as a change relative to background activity. Next, head-normalization is done, such that Rk is 
divided by R1 within each time point for an hjk matrix. Head-normalization accounts for day-to-day 
variables such as injected luciferin amount and systemic NF-κB changes. 
 
Therapeutic Focused Ultrasound 
Focused ultrasound (FUS) was used to deposit either thermal or mechanical energy into the tissue. 
A waveform generator (Agilent 33511B, Agilent, Santa Clara, CA USA) and radio frequency amplifier (E&I 
A150, Electronics & Innovation, Ltd. Rochester, NY USA) were used to create the ultrasound signal, which 
was then focused by the FUS transducer (H-101MR single element, 1.1 and 3.3 MHz operation, 400W, 
Sonic Concepts, Bothell, WA, USA). The transducer was fixed into place at the base of an open-tipped 
plastic cone, which was subsequently filled with vacuum-degassed water. An acoustically transparent 
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latex membrane sealed the open tip of the cone, and ultrasound gel was used to couple the cone to mice, 
such that it was in contact with the skin over the tissue to be treated.  
Thermal FUS was guided with a closed-loop feedback system, employing magnetic resonance-
thermometry (MRT) to monitor and control thermal dosing in real-time (Figure 4). Detailed in Poorman 
et al,129 during hyperthermia FUS (hFUS) treatment, the murine subject was affixed to a platform with the 
tissue of interest placed on the treatment surface of the ultrasound transducer cone. A heated-water pad 
was positioned between the mouse and platform to maintain body temperature, and inhaled isoflurane 
anesthesia was maintained via breathing tube and nose cone. During treatment, constant surveillance of 
temperature and respiratory rate were monitored with a rectal thermometer and an attached respiratory 
monitor pad, respectively. The entire treatment platform was placed into a Varian 4.7T magnetic 
resonance imaging system for treatment. Output voltage of the waveform generator was determined by 
the real-time feedback loop, to achieve and maintain a 6 °C change in temperature from baseline. An 
output voltage limit was set for 70 mV, corresponding to approximately 1.5 MPa peak negative pressure, 
to minimize cavitation activity. 
Mechanical FUS (mFUS) treatment employed the same treatment platform used for hFUS, but 
treatments were conducted on a benchtop, without MR imaging. Mice were similarly anesthetized, 
however, no heated-water pad, breathing monitor, or thermometer were required. Sonication was 
conducted at the 1st harmonic (center frequency of 1.1 MHz) with either high level mFUS (mFUS-high) or 
low level mFUS (mFUS-low). The peak negative pressure (PNP) induced by sonication is related to the 
amplitude of voltage used. A calibration curve was generated measuring the pressure changes in a 
phantom at specific voltages to generate a linear regression; however, the relationship is non-linear at 
high driving voltages. For this reason, the PNP values of the two mFUS treatment levels were calculated 
with the linear regression and adjusted by a factor of approximately 0.75 for low mFUS and 0.65 for high 
mFUS, similar to the work done by Maxwell et al130. High level mFUS was done using an 8.5 MPa PNP burst 
24 
 
with a period of 20.00 msec, and 22 kilocycles for five applications of 60 seconds with a repetition 
frequency of 1 Hz. After each 60-second application, the transducer was moved slightly to treat have a 
different focal point within the same tumor. Low level mFUS was done using an 8 MPa PNP burst with a 
period of 1 msec, and 1100 cycles for one application of 30-60 sec with a repetition frequency of 1 Hz. 
Preliminary trials of hFUS were conducted in the flank of NGL-only mice to verify that FUS-induced 
changes in NF-κB activity would be observed and detectible by IVIS. PyNGL tumor experiments were 
performed with FUS treatment of a single primary tumor per treated mouse. Mice received FUS when the 
tumor to be treated reached a diameter of at least 1 cm.   
 
 
Figure 4. MR-guided FUS feedback loop for controlled hFUS treatment. For treatment, the mouse 
(specifically the tumor) is placed onto the FUS transducer, then the mouse and transducer are placed into 
the bore of a 4.7T MR imaging system. MR thermometry is used to monitor and control thermal dosing. 
MRT is based on the way protons act in a magnetic field51, which is dependent on a known relationship 
with temperature, so MR images are taken prior, and throughout, ultrasound treatment. With each 
subsequent image, the baseline activity image is subtracted in real time to create a temperature map. 
Using this map, temperature at the focal spot in the tissue can be quantitatively traced during treatment. 
A target temperature of ∆6 ⁰C is set for the focal spot and used in conjunction with the temperature map 
to turn the ultrasound on and off as needed to reach and maintain target heating. There is an initial lag 
time during which energy deposition into the tumor ramps up to reach this target temperature, then the 
feedback system allows automatic maintenance of this temperature in the tumor tissue throughout the 
treatment, 5 minutes of which is shown in the Focus Temperature graph. 
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Tissue Collection 
 At 48 hours post-treatment mice were euthanized and tissues collected into ice-cold DPBS 
(Dulbecco’s Phosphate Buffered Saline, 1X without calcium & magnesium). For untreated mice, this time 
point was selected based on when the mouse would have been treated according to tumor size (described 
above in Bioluminescent in vivo Imaging). A portion of each collected tumor was stored in 10% formalin 
(4% Formaldehyde Solution, Fisher Scientific) for tissue fixation. In treated mice, the mechanically treated 
tumor (MTT), an untreated tumor within the treated mice (contralateral tumor (CLT)), and the spleen 
were collected. In untreated mice, one or more untreated tumors (UTTs) were collected, including the 
largest tumor for similarity to MTTs, as well as the spleen. Tissues were mechanically dissociated with a 
straight razor blade and subsequently filtered through 70 µm nylon mesh filters (Fisher Scientific, 
Pittsburgh, PA). The resulting cell suspensions were centrifuged, supernatant collected and frozen at -20 
°C, and pellets resuspended in 1 mL ACK lysing buffer (KD Medical Inc., Columbia, MD) for 2 minutes before 
dilution with 20 mL ice-cold DPBS. Suspensions were centrifuged again, supernatant aspirated away, and 
pellets resuspended in 600 µL DNase (DNase I, RNase-free, BioRiad, Hercules, CA) in HBSS (Hanks’ 
Balanced Salt Solution, 1X with calcium and magnesium). The DNase-cell suspension was kept at room 
temperature for 30 minutes and diluted with ice-cold DPBS. After a final centrifuge step, supernatant was 
aspirated away, and pellets were resuspended in 2 mL of 90% FBS with 10% DMSO.  The final cell 
suspension was aliquoted into cryovials and frozen. Cryovials were cooled at a rate of -1 °C/minute to -80 
°C before transfer to liquid nitrogen. All centrifuge steps were conducted at 200 xg for 10 minutes at 4 °C. 
 
Flow Cytometry  
 Cells were rapidly thawed from liquid nitrogen, resuspended in 10 mL ice-cold DPBS, centrifuged, 
and the pellets resuspended into ice-cold DPBS. Cells were stained with the following rat anti-mouse 
antibody-fluorochrome conjugates: 1 µg/106 cells of CD3-AlexaFluor 700 (clone 17A2, BD Biosciences, San 
26 
 
Jose, CA), 0.09 µg/106 cells of CD4-FITC (clone RM4-4, BD Biosciences, San Jose, CA), and 0.01 µg/106 cells 
of CD8b-PE (clone H35-17.2, BD Biosciences, San Jose, CA). After incubation with the antibodies for 30 
minutes at room temperature, cells were washed twice with DPBS, and resuspended in 2 mL 75% 
methanol in DPBS with 1.2 µg/106 cells Hoechst (Hoechst 33342, trihydrochloride, trihydrate, 10 mg/mL 
solution in water, Life Technologies) for 30 minutes at room temperature. Cells were centrifuged at 900 x 
g for 15 minutes at 4 °C, resuspended in 500 µL DPBS, and analyzed with a BD LSRFortessa (Beckton-
Dickson, San Jose, CA USA) flow cytometer. 
 
Flow Cytometry Gating 
 The gating strategy employed (Figure 5) was used for doublet elimination, selection of DNA-
containing cells, lymphocyte gating, and T cell isolation and phenotyping. Side scatter (SSC), a measure of 
cell granularity131, was used to eliminate doublets based on the approximation of a 1:1 ratio for SSC-area 
(SSC-A) and SSC-height (SSC-h) expected for single cells. Forward scatter (FSC), a measure of cell size131, 
was similarly used to eliminate doublets by the expected 1:1 ratio of FSC-area (FSC-A) and FSC-height (FSC-
H) expected for single cells. Following doublet elimination, single cells are identified by positive Hoechst 
staining for the presence of DNA, eliminating debris aggregates. Lymphocytes are identified by the known 
relationship between their size and granularity132,133, and T cells are then selected by the presence of CD3+ 
(general T cell marker). T cells are then further classified by the presence of either CD4+ (helper and 
regulatory T cells) or CD8+ (cytotoxic T cells).   
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Figure 5. The flow cytometry data shown, from the spleen of a mouse treated with mFUS, is representative 
of the gating process used to analyze tissues from 14 mice. Single cells were isolated by: (A) doublet 
exclusion by SSC-A: SSC-H ratio, (B) doublet exclusion by FSC-A : FSC-H ratio, and (C) uniform DNA content 
determined by Hoechst+. (D) Lymphocytes were isolated with standard SSC-A versus FSC-A gating for size 
and granularity131. (E) T cells were selected based on CD3+ staining, and (F) were subsequently 
phenotyped based on either CD4+ or CD8+ staining.  
 
Immunohistochemistry 
 Tumor portions that were formalin-fixed at the time of tissue collection were subsequently 
processed in the Vanderbilt Translational Pathology Shared Resource (TPSR). Tissues were paraffin-
embedded and sectioned with 5-µm thickness. From each tumor, a minimum of two sections were 
obtained and mounted on separate slides. One section was stained with hematoxylin & eosin. For 
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immunohistochemistry staining of the two other mounted tissue sections, slides were placed on the Leica 
Bond Max IHC stainer. All steps besides dehydration, clearing and coverslipping are performed on the 
Bond Max. Slides are deparaffinized. Heat induced antigen retrieval was performed on the Bond Max 
using their Epitope Retrieval 2 solution for 20 minutes. One slide per tissue was incubated with anti-Foxp3 
(Cat#13-5773-82, eBioscience, Inc., San Diego, CA) for one hour at a 1:100 dilution and followed by a 
biotinylated anti-rat (Cat#BA-4000, Vector Laboratories, Inc., Burlingame, CA) for 15 minutes at a 1:200 
dilution. The Bond Polymer Refine Detection system (Cat#DS9800, Leica Biosystems, Newcastle Upon 
Tyne, United Kingdom) was used for visualization. The other slide for each tissue was then incubated with 
anti-CD4 (Cat#14-9766-80, eBioscience Inc, San Diego, CA) for one hour at a 1:1000 dilution and then 
incubated in a rabbit anti-rat secondary (BA-4001, Vector Laboratories, Inc.) for 15 mins at a 1:200 
dilution. The Bond Polymer Refine Red Detection system (Cat#DS9390, Leica Biosystems, Newcastle Upon 
Tyne, United Kingdom) was used for visualization.  Slides were then dehydrated, cleared and coverslipped. 
 Slides were imaged at the Vanderbilt Digital Histology Shared Resource using the Leica SCN400 
Slide Scanner (Leica Microsystems Inc., Buffalo Grove, IL) and image analyses were conducted using the 
Digital Image Hub (Leica Biosystems, Nussloch, Germany). Separate slides from each tissue section imaged 
following staining for CD4 or FoxP3, with CD4+ stained cells including both Thelper and Treg cells. FoxP3 
staining was used to identify Treg (FoxP3+) cells and calculate the percent of CD4+ cells which were Treg and 
Thelper. Multiple location-matched regions of interest were selected on both stained slides from each 
tissue. Within corresponding ROIs, the number of CD4+ or FoxP3+ stained cells, respectively, were 
counted and taken as a percent of total cells within the region of interest. The percent of CD4+ T cells of 
the Treg phenotype was calculated as the ratio of % of cells FoxP3+ cells divided by % of cells CD4+; the 
remainder of CD4+ cells were identified as Thelper cells. 
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Cytokine Analysis by Flow Cytometry 
 The supernatant collected and frozen during tissue processing was used to assess relative 
expression of cytokine levels. We designed a multiplexed cytometric bead array, selecting combinable kits 
from the enhanced sensitivity (ES) flexible set options (BD Biosciences, San Jose, CA) to measure IL-6, IL-
2, IL-10, IL-17a, TNF-α, and IL-1β. The kit includes known lyophilized amounts of the selected cytokines 
(standards), wash buffer, mouse detection reagent (antibody), enhanced sensitivity detection reagent 
(fluorescent antibody), and capture beads, which are microscopic beads coated with antibodies for a 
specific cytokine. All of the ES capture beads have varying levels of two fluorophores (APC and APC-Cy7). 
The relative intensities of bead fluorescence relative to the other beads in the set allows multiple cytokine 
capture beads to be used in conjunction for multiplexed analysis of a single sample. The detailed protocol 
is available through the BD Biosciences website134. Briefly, capture beads for the six selected cytokines 
were mixed in equal parts.  Standards were mixed in equal parts for each cytokine, and then serially 
diluted for solutions with known cytokine concentrations. The frozen supernatants were thawed and 25 
µL of each were placed into separate tubes. The ES capture bead mixture was added to each sample and 
standard tube and allowed to incubate for 2 hours at room temperature. Mouse detection reagent was 
added to each tube and incubated for an additional 2 hours. The mouse detection reagent is an antibody 
specific to the mouse Fc-region. The samples were washed, resuspended with enhanced sensitivity 
detection reagent, and incubated for 1 hour. Similarly, the enhanced sensitivity detection reagent is a 
fluorescent antibody specific to the Fc-region of the mouse detection reagent. The samples were then 
washed, resuspended in wash buffer, and analyzed on a BD LSRFortessa (Beckton-Dickson, San Jose, CA 
USA) flow cytometer. 
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Statistical Analysis 
 Statistical analyses were conducted with GraphPad Prism (GraphPad Software, Inc., La Jolla, CA). 
The Mann-Whitney test was used to determine statistical significance, with p < 0.05. 
 
Results and Discussion 
 
FUS Generates Measurable NF-κB Changes in NGL Mouse Flank 
 Prior to breeding the double-transgenic PyNGL model, a preliminary study was conducted using 
FUS therapy in the flank of a non-tumor bearing NGL mouse. IVIS data was collected and processed as 
described, with regions of interest for the head (R1), an untreated area of the flank (R2), and the hFUS 
treated area of the flank (R3), to characterize changes in NF-κB pathway activity. Figure 6 shows IVIS 
images at 0 and 48 hour time points for two mice, where Mouse α was treated on its right flank with hFUS 
at ∆6 °C for 10 minutes, while Mouse β was untreated. The processed radiance data (Figure 3) suggests 
FUS treatment induced a change in NF-κB activity in treatment-localized tissue.  
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Figure 6. NGL mice were imaged with IVIS prior to treatment and 48 hours after treatment. Image 
exposure settings were automatically determined by the imaging software. Mouse α was treated with 
hFUS on the right flank and Mouse β was untreated. The graph shows a ratio of right flank ROI normalized 
radiance to left flank ROI normalized radiance. While the ratio of right to left flank in Mouse β is roughly 
1, the ratio for Mouse α is approximately 3. This indicates that, following treatment, the treated right flank 
of Mouse α has nearly 3 times more NF-κB activity. For this preliminary flank study, n = 1 for hFUS and  
n = 1 for no treatment, therefore no statistical analyses were conducted. 
 
Sequence Imaging is Necessary for ROI Maximum Radiance 
Initial studies suggested variation in the biodistribution of intraperitoneally injected luciferin. 
Contralateral tumor radiance for an imaging sequence at a single, pre-treatment time point is shown for 
four mice in Figure 7A. The trajectory of sequence radiance approximates a logarithmic curve, and the 
maximum value is reached at different times following injection. Figure 7B shows the percent error that 
would occur if a single measurement were taken at 16 minutes after injection. These variations may be 
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attributed to biological variability between mice, tumor vasculature, or IP injection. Sequence imaging 
ensures maximum values can be measured and normalized for comparison between time points. 
 
 
Figure 7. Following luciferin injection, a sequence of IVIS images were collected, with a delay of 60 seconds 
between consecutive images. Image exposure settings were automatically determined by the imaging 
software. A) Plot of CLT radiance over the sequence of images collected at one pre-treatment time point 
for 4 mice (J, K, N, and I). The maximum radiance value, indicated on each data set by “X”, ranges in 
magnitude and time to occurrence following injection. B) Sequence radiance of the ROI for the mice and 
time points in (A) was used to calculate percent error comparing maximum ROI radiance to ROI radiance 
at 16 minutes after injection. The two-step normalization process was not used for single time point 
analysis.  
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NF-κB BLI Indicates Temporal Changes of Response to Treatment 
Successful cross breeding of the PyMT and NGL models resulted in the generation of the PyNGL 
double-transgenic mouse model, as verified by tail-cut genotyping for the presence of GFP and PyMT 
transgenes (Transnetyx, Inc., Cordova, TN). The first hFUS treated PyNGL mouse was imaged with IVIS for 
2.5 weeks following treatment. Using this IVIS data (Figure 8), the radiance, linked to NF-κB activity levels, 
in the hyperthermia-treated tumor (HTT) decreased to approximately 50% of baseline values at 48 hours 
and stayed below baseline for the remaining time points, suggesting a change in NF-κB activity, potentially 
as a result of FUS treatment. The primary focus of the completed studies was to characterize early 
adaptive response in FUS-treated tumors (HTTs and MTTs). Based on this time course information (Figure 
8), the maximum change from baseline in the HTT occurred at 48 hours, therefore tissue collection from 
subsequent mice was done at 48 hours following treatment.   In untreated animals, the baseline and 48-
hour time-points were selected based on when the animals would have been treated according to tumor 
size. 
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Figure 8. In vivo BLI images are taken before and after treatment. Image exposure settings were 
automatically determined by the imaging software. This figure is a representative example (1 hFUS-
treated mouse) of IVIS images and trajectory. IVIS images shown were taken at 0 hours, to measure 
background NF-κB activity prior to treatment, and at 12, 48, and 120 hours following treatment. Purple 
circles denote the three defined regions of interest: head, contralateral tumor (CLT), and hyperthermia-
treated tumor (HTT). Baseline NF-κB activity at 0 hours is noted primarily in the head, mammary glands, 
and regions of exposed skin, such as the tail and paws. The normalized radiance data for CLT and HTT is 
plotted. At 12 hours, both CLT and HTT have increased slightly from baseline. By 48 hours, HTT has 
decreased to approximately 50% of baseline activity, which is maintained through 470 hours. In contrast, 
CLT increased more than 150% from baseline, reaching a peak at 143 hours before trending back towards 
baseline activity level. A total of 2 mice were analyzed in this way to establish the most appropriate time 
for subsequent analyses. 
 
Similarly, mice treated with mFUS were imaged every 12 hours for 48 hours following treatment 
to identify time-course changes in radiance. Figure 9 depicts the change in normalized tumor radiance for 
untreated and mFUS-treated mice. From Figure 9.A, both the average MTT and CLT-M (contralateral 
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tumors from mFUS-treated mice) normalized radiance values increase from baseline to 48 hours. This 
shows a change that occurs in NF-κB activity by 48 hours, supportive of the decision to collect tissues 48 
hours after treatment. While Figure 9.A depicts averages with standard error for UTTs, MTTs, and CLT-Ms, 
Figure 9.B shows individual measurements for MTTs and representative UTTs. At 48 hours post-treatment, 
two MTTs exhibit an increase from baseline of approximately 200% (Figure 9.B). This change in normalized 
average radiance is distinctly different from the response observed in the UTTs and in the other three 
MTTs. Additionally, normalized average radiance at the 12 hour time point did not predict for response at 
48 hours. This indicates that the time course and level of NF-κB response varies between animals, 
potentially arising from variations in pre-treatment tumor microenvironment. Statistical analysis of this 
data is shown in Figure 10, along with IVIS data from an additional treatment group. 
 
 
Figure 9. Normalized radiance, shown as relative change from baseline. (A) Time course of aggregate data 
plotted as mean with standard error, includes UTT, MTT, and CLT for mFUS (CLT-M). (B) Time course for 
individual mice: 5 MTTs and 4 UTTs. One untreated mouse was imaged with exposure settings 
automatically determined by the imaging software.  Error bars show standard error for each tissue and 
time point. 
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BLI Indicates Treatment-Response Relationship 
Tumors from PyNGL mice were treated with FUS or no treatment and subsequently imaged with 
IVIS. Figure 10 depicts the normalized IVIS data at 48 hours after treatment from 5 mFUS-treated mice, 6 
hFUS-treated mice, and 4 untreated mice. In each untreated control mouse, four UTT’s were selected to 
account for inter-mouse variability. At the 48-hour time point, a statistically significant increase in 
radiance was observed in MTTs as compared to UTTs, demonstrating a direct effect of mFUS on tumor 
NF-κB activation levels. Furthermore, contralateral tumors in mFUS-treated mice (CLT-Ms) exhibit a 
similar response, with a statistically significant increase compared to UTTs. The response detected in 
distant, untreated tumors (CLT-Ms) suggests that, in addition to the direct effect of mFUS on the treated 
tumor, mFUS is also capable of generating a distant response. Large variability is seen in mFUS treated 
tumor measures, with two subjects having experimental values for both MTT and CLT-M exhibiting a 
change from baseline ranging from 180-270%. These two experimental subjects cause the statistical 
significance seen between UTTs and MTTs or CLT-Ms, suggesting a subset of mice which may have a more 
substantial NF-κB response to mFUS treatment. In contrast, no statistical difference was observed 
between HTTs and UTTs; however, CLT-Hs did exhibit a statistically significant increase over UTTs, 
indicating that, while no direct effect on HTTs was observed, a remote effect was generated. The reporter 
model provides a basis for relating radiance to activation of the NF-κB pathway. Increased radiance 
observed in MTTs but not HTTs, as compared to UTTs, supports the idea that mFUS and hFUS operate by 
different mechanisms of action60. The remote response in CLT-Ms and CLT-Hs suggests that both mFUS 
and hFUS have the potential to induce a systemic, abscopal effect. 
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Figure 10. Normalized IVIS data for 15 PyNGL mice 48 hours after treatment. Treatment groups include 5 
mFUS-treated mice (MTT & CLT-M), 6 hFUS-treated mice (HTT & CLT-H), and 4 untreated mice (UTT). 
Displayed, 4 UTTs were included per untreated mouse for a total of 16 UTT values. One untreated mouse 
and all hFUS treated mice were imaged with exposure settings automatically determined by the imaging 
software. Mean and standard error are shown in black for each ROI. The two-tailed Mann-Whitney test 
was used to assess statistical significance. The pairs: MTT – UTT, CLT-M – UTT, and CLT-H – UTT had values 
of *p < 0.05. All other pair-wise analyses had values of p > 0.05. 
 
While Figures 9 and 10 present data for a single CLT-M from each mFUS treated mouse, the 
spontaneous model develops multiple fat pad tumors. Figure 11 shows normalized average radiance 
where four tumors were included per mouse – four UTTs per untreated mouse, and one MTT with three 
CLT-Ms per mFUS treated mouse. Statistical significance is maintained between UTTs and CLT-Ms when 
multiple CLT-Ms are included per mouse, while no significant difference exists between CLT-Ms and MTTs. 
This confirms that the mFUS-induced change in radiance is systemic, further supporting a potential 
abscopal effect. 
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Figure 11. Normalized IVIS data for 9 PyNGL mice 48 hours after treatment. Treatment groups include 5 
mFUS-treated mice (MTT & CLT-M) and 4 untreated mice (UTT). Displayed, 4 UTTs were included per 
untreated mouse for a total of 16 UTT values and 3 CLT-Ms were included per mFUS treated mouse for a 
total of 15 CLT-M values. One untreated mouse was imaged with exposure settings automatically 
determined by the imaging software. Mean and standard error are shown in black for each ROI. The two-
tailed Mann-Whitney test was used to assess statistical significance. The pairs: MTT – UTT and CLT-M – 
UTT had values of *p < 0.05, while MTT – CLT-M had a values of p > 0.05. 
  
Flow Cytometry Indicates T Lymphocyte Shift 
Quantitative analysis of flow cytometry data (Figure 12) reveals significant differences in immune 
cell populations among treated and untreated tissues. Initially, group analyses were conducted in a binary 
manner, such that mice were either untreated or mFUS-treated. Binary group analysis of flow cytometry 
data revealed a larger range of values for MTTs than for UTTs, suggesting that mFUS treatment may induce 
a more significant immune response in a subset of treated animals. Consequently, mFUS-treated mice 
were further classified as responders or non-responders to mFUS treatment, selected for highest percent 
of CD3+ T cells in the spleen. This criteria was selected based on the critical role of the spleen as a 
secondary lymphoid organ, where antigen presenting cells and adaptive immune cells accumulate from 
circulation135,136. The dense presence of both cell types provides an environment suitable for antigen 
presentation and cross-presentation to lymphocytes. Categorization of mFUS-treated mice into responder 
and non-responder groups is based on the understanding that the efficacy of a given immunotherapy 
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varies widely among patients; while some patients may experience complete remission, others may have 
no response. Separation of responders from non-responders allowed extrication of treatment-induced 
effects in mice receptive to mFUS-induced immunological changes.  
Previous studies have demonstrated that an increased CD4+/CD8+ ratio is associated with 
improved outcomes90, and can be generated in tumors with FUS treatment97.  The CD4+/CD8+ T cell ratio 
in tissues of untreated mice was not statistically different from that of mFUS-treated mice (Figure 12.A); 
however, analysis of the CD4+/CD8+ ratio for mFUS-treated mice considered separately as responders 
(Figure 12.B) and non-responders (Figure 12.C) revealed significant difference in the ratio between 
responder MTTs and UTTs. Similarly, the percent of T cells which were CD4+ in responder MTTs was 
statistically higher than UTTs (Figure 12.E), while no statistical difference from UTTs was observed for 
combined MTTs (Figure 12.D) or non-responder MTTs (Figure 12.F). Interestingly, the percent of CD4+ T 
cells, when comparing spleens of treated mice (SPL-Tr) to spleens of untreated mice (SPL-Un), is 
statistically higher for combined SPL-Tr (Figure 12.D) and non-responder SPL-Tr (Figure 12.F), but not for 
responder SPL-Tr (Figure 12.E). The percent of T cells which were CD8+ in tissues of untreated mice was 
not statistically different from those of treated mice, whether considering combined mFUS-treated mice 
(Figure 12.G), responders (Figure 12.H), or non-responders (Figure 12.I). Together these data suggest that, 
in the responder subset of mFUS-treated mice, a change was induced in the T cell profile. Additionally, 
the increased CD4+ T cells in the spleens of non-responders may indicate potential for an immunological 
change in these mice. The non-responders may have different response kinetics with CD4+ T cells still 
undergoing proliferation in the spleen, or these animals may be undergoing an alternate type of immune 
response.  
The 48 hour time-point was selected based on pilot mice following FUS treatment-modulated NF-
κB activation. It is possible that immune cell response to FUS lags NF-κB activation resulting in the 
observed variability of T cell response at 48 hours. Longer post-treatment observation times may provide 
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a more comprehensive view of T cell infiltration and impact on tumor burden, as well as insight into the 
differences between responders and non-responders. 
 
 
Figure 12. Quantified flow cytometry data are shown from untreated tumors (UTTs), mFUS-treated 
tumors (MTTs), and spleens from the corresponding untreated and mFUS-treated mice (SPL-Un and SPL-
Tr, respectively). Using the described gating strategy, T cells (CD3+) were phenotyped based on expression 
of either CD4+ or CD8+ markers. In addition to the percent of T cells which were CD4+ or CD8+, the ratio 
of CD4+/CD8+ T cells was also assessed. For all three measures, the range of MTT values exceeded that of 
UTT, leading to subclassification of mFUS-treated mice into two response categories: responders and non-
responders. Results for untreated mice are shown with data for aggregated mFUS-treated mice (left 
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column), responders (middle column), and non-responders (right column). (A-C) Ratio of T cells which 
were determined to be CD4+ versus CD8+ (CD4+/CD8+ ratio), shown for (A) aggregated mFUS-treated 
mice, (B) only responders, and (C) only non-responders. (D-F) Percent of T cells which are CD4+, shown 
for (D) aggregated mFUS-treated mice, (E) only responders, and (F) only non-responders. (G-I) Percent of 
T cells which are CD8+, shown for (G) aggregated mFUS-treated mice, (H) only responders, and (I) only 
non-responders. Mean and standard error are shown in black for each tissue. The one-tailed Mann-
Whitney test was used for statistical analysis (*p < 0.05). 
 
Histology and IHC 
 Examination of histology data (Figure 13) reveals a prevalence of hyperchomatism in the UTT 
(Figure 13.A) and a higher presence of pale eosinophilic staining regions in MTTs (Figure 13.B). This 
structural information suggests that cell death tends to be largely necrotic in MTTs and apoptotic in 
UTTs137.  Necrotic cell death is a better stimulator of adaptive immunity than apoptotic death138. 
Additionally, the MTT exhibits a tortuous morphology not seen in the UTT; this may point to structural 
changes caused by mFUS treatment. 
Representative images of IHC slides are shown for a UTT, stained for all CD4+ T cells (Figure 13.C) 
and FoxP3+ Treg cells (Figure 13.D). Quantitative analysis of IHC (Figure 13.E) shows a presence of Thelper 
and Treg cells in both MTTs and UTTs, however, the Thelper/Treg ratio is statistically increased in MTTs, 
suggesting a more pro-inflammatory, anti-tumor balance in MTTs than in UTTs.  
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Figure 13. Histology and IHC were used for further characterization of mFUS-induced intratumoral 
changes. Representative images of H&E, acquired at 4x magnification, are shown for A) a UTT and B) an 
MTT. Representative IHC images, acquired at 10x magnification, are shown for a UTT stained brown for 
C) CD4+ T cells [arrows] and D) FoxP3+ T cells [circles]. E) Phenotyping of CD4+ T cells in 4 MTTs and 4 
UTTs; the data shows a relative increase in Thelper cells and decrease in Treg cells for MTTs compared to 
UTTs. Mean and standard error are shown. The one-tailed Mann-Whitney test was used for statistical 
analysis (*p < 0.05). 
 
Cytokines 
 Analysis of cytokine levels in tissues of untreated and mFUS-treated mice (Figure 14) suggests 
variation. These experimental results were obtained during a pilot run using the BD enhanced sensitivity 
cytometric bead array. During this trial, IL-1β, IL-2, IL-6, IL-10, IL-17α, and TNF were measured. In the 
spleens, all six cytokines were present at measurable concentrations; however, in the tumors, the 
concentrations of IL-2, IL-10, and IL-17α were below the threshold of detection. Figure 14.A shows the 
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relative level of each of the three detectable cytokines—IL-1β, IL-6, and TNF—cytokine in four tumors (2 
UTTs and 2 MTTs) as a percent of the summed concentrations, taken from the same initial volume.  
Similarly, the level of each cytokine in the corresponding spleens (Figure 14.B) is presented as a percent 
of the summed concentrations of all six measured cytokines.  
 
 
Figure 14. Cytokine measurement results using the enhanced sensitivity CBA kit. Cytokines were measured 
from tissue digestion supernatants for UTTs, MTTs, and SPLs. Mice AB and AJ were not treated, while mice 
AH and AD were mFUS-treated. No statistical analysis was conducted due to small sample size. 
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Conclusion and Future Work 
 
BLI of PyNGL Mice 
 The novel PyNGL double-transgenic murine reporter model was successfully developed and 
imaged with BLI for temporal snapshots tracking luminescence-linked NF-κB activation. The ubiquitous 
nature of NF-κB throughout the PyNGL mice presented a unique window to broadly visualize FUS-induced 
changes in treated and contralateral tumors but was accompanied by the challenge of resolving 
treatment-induced changes from background activity. A two-step radiance normalization process was 
designed and applied, producing results in untreated mice, which were consistent among tumors within 
each mouse, as well as among mice. This suggests that the normalization process reliably resolves NF-κB-
coupled radiance changes within mice, allowing each animal’s pre-treatment measurements to function 
as its own control. Analysis of IVIS measurements using the Mann-Whitney test, suggest that NF-κB 
activation in MTTs and CLTs for mFUS and hFUS (CLT-M and CLT-H, respectively) are statistically different 
from UTTs at 48 hours after treatment. The change in radiance for CLTs of both mFUS and hFUS treatments 
suggests that MTTs and HTTs interact with distant tumors, indicating potential for local and abscopal 
effects.  
 
Cellular and Molecular Tissue Characterizations 
 Preliminary assessment of flow cytometry data revealed a larger range of values for MTTs than 
UTTs, prompting the classification of mFUS-treated mice as responders and non-responders based on the 
percent of CD3+ cells in the spleen.  Flow cytometry results for tumors and spleens of untreated and mFUS 
treated mice revealed statistically significant differences in the lymphocyte populations. The percent of 
CD4+ T cells is higher in responder MTTs than in UTTs, as is the CD4+/CD8+ T cell ratio. An increased 
CD4+/CD8+ ratio has been found to be beneficial in the context of certain types of cancer, and is likely 
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due to the supportive role that CD4+ T helper cells play in CD8+ T cell effector functions, particularly 
cytokine moderation of T cell expansion.139 Our results are consistent with previously reported 
cavitation140 and ablation97 FUS-induced changes. Interestingly, the percent of CD4+ T cells is higher in the 
spleens of non-responder mice than in untreated mice, suggesting that these mice may have a delayed 
immune response and still be in the T cell proliferation phase.  
Further phenotypic characterization of CD4+ T cells was carried out on tumor sections with IHC, 
staining for CD4+ and FoxP3+ cell expression. Analysis of IHC sections revealed a higher ratio of Thelper/Treg, 
pointing to a potential mFUS-induced shift from immune suppression towards immune activation. Future 
work will include immunofluorescence (IF) staining, so multiple markers of interest may be identified on 
each tissue section. The IF antibody panel will include anti-CD4, anti-FoxP3, anti-CD8, anti-CD45 and anti-
GFP, along with markers for nuclei and stroma. These will allow distinction of various T cell phenotypes 
(CD4, FoxP3, CD8), immune cells (CD45), and NF-κB activation (GFP), while the nuclei and stromal markers 
provide structural information regarding the localization of immune cells. The CD45/GFP combination will 
relate NF-κB activation to general cell types to compliment in vivo imaging data with higher specificity.  
More robust analyses of IHC and subsequent IF are required to verify the initial conclusions.  
The TME has a critical, complex role in the therapeutic response to immunotherapy. Cytokines 
are key moderators of the TME, and preliminary assessment revealed some notable differences, 
particularly between HTTs and UTTs. The cytokine levels in HTT indicate a potentially significant difference 
in IL-6 and TNF-α, which suggest some hFUS-induced TME modifications. Further testing is required to 
characterize the levels in more samples for UTTs, MTTs, CLT-Ms, HTTs, and CLT-Hs. Future experiments 
with the CBA enhanced sensitivity flex sets will include IFN-γ in addition to the six cytokines tested 
previously. 
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Scope of Work 
Combining immunology, biology, imaging, and engineering, this project would not have been 
possible without the multidisciplinary team of collaborative experts. The animal treatments and 
corresponding collection of data is enumerated in Table 3. The treatment types include: none (untreated), 
mFUS-high, mFUS-low, and hFUS. Tissue samples which will be processed by flow cytometry include 3 
spleens from untreated mice, 2 mFUS-low treated tumors and their 2 corresponding spleens. Refrigerated 
maintenance was unsuccessful for tissues from 9 untreated mice and 11 hFUS-treated mice. Samples 
required for histology, IHC, and cytokine analysis are available for all 36 mice, and processing of these 
samples is currently underway. 
 
Table 3. Summary of mice used for FUS treatments, IVIS imaging, and flow cytometry. 
  
 
Outcomes and Impact 
 We have developed the PyNGL model, the first-ever tool for monitoring whole tissue NF-κB 
activation in a spontaneous model of breast cancer. This model is particularly useful in our study, in which 
two forms of FUS, hFUS and mFUS, were administered to tumors as a source of inflammatory stimulus. 
The spontaneous nature of the tumors, and their subsequent metastatic progression, more closely model 
certain aspects of human disease than many orthotopic and cell line tumor models. Furthermore, the 
Treated tumor 
(UTT, MTT, & HTT)
Spleen
None 4 6 6 15
mFUS-high 5 6 6 6
mFUS-low 0 2 2 4
hFUS 6 0 0 11
Total (Data) 15 14 14 36
Flow Cytometry
Treatment IVIS
Total 
(Mice)
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PyNGL model maintains an intact immune system, allowing interactions between innate and adaptive 
immune cells, a crucial factor for assessing therapeutic response.  
Using BLI as a method for non-destructive, in vivo imaging, snapshots of NF-κB activity at multiple 
time points before and after treatment enables assessment of temporal response. As with other detection 
techniques, a tradeoff between sensitivity and specificity exists; the ubiquitous presence of the NF-κB 
pathway in all cells lends itself to high sensitivity for a variety of therapeutic response mechanisms, with 
low specificity for distinguishing the type of response. However, the presence of the reporter transgene 
in all cells of the PyNGL model creates a window to monitor both local and systemic changes, which would 
not be possible with the use of a wild-type mouse developing tumors with a tumor cell-specific reporter 
transgene. As a consequence, background NF-κB activity, particularly high in the tumors, creates noisy 
data and images. Development of the described data acquisition and normalization techniques provides 
a method for improved sensitivity detection of changes from baseline, some of which may not be 
discernable with visual inspection of the images. The PyNGL model was developed as a tool to more 
efficiently inform therapeutic studies for use in tandem with advanced response characterization 
techniques.  
Flow cytometry analysis of tumors and spleens reveal mFUS-induced changes in immune profile. 
The distinction of responders and non-responders may indicate that the response mechanism or timeline 
is varied between animals, and pre-treatment immunogenicity may play a role in treatment response. 
While the 48-hour time point may be optimal for NF-κB activation, the cellular immune response may lag 
temporally.  Collection of tissues at additional time points, survival studies, and combination therapy with 
FUS and immunomodulatory agents are necessary to definitively characterize the impact of mFUS 
therapy. Additionally, assessment of cytokines within the tumors, as well as further classification of CD4+ 
T cells into helper and regulatory categories, will provide more insight into the tumor immunity response 
mechanisms.   
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